Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 160

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Kinesin Spindle Protein (KSP) Inhibitors. 9. Discovery of (2 S)-4-(2,5-Difluorophenyl)-N-[(3 R,4 S)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1 H-pyrrole-1-carboxamide (MK-0731) for the Treatment of Taxane-Refractory Cancer

Open access
Cox, Christopher D., Coleman, Paul J., Breslin, Michael J., Whitman, David B., Garbaccio, Robert M., Fraley, Mark E., Buser, Carolyn A., Walsh, Eileen S., Hamilton, Kelly, Schaber, Michael D., Lobell, Robert B., Tao, Weikang, Davide, Joseph P., Diehl, Ronald E., Abrams, Marc T., South, Vicki J., Huber, Hans E., Torrent, Maricel, Prueksaritanont, Thomayant, Li, Chunze, Slaughter, Donald E., Mahan, Elizabeth, Fernandez-Metzler, Carmen, Yan, Youwei, Kuo, Lawrence C., Kohl, Nancy E., Hartman, George D.·2008·Journal of Medicinal Chemistry

Abstract

Inhibition of kinesin spindle protein (KSP) is a novel mechanism for treatment of cancer with the potential to overcome limitations associated with currently employed cytotoxic agents. Herein, we describe a C2-hydroxymethyl dihydropyrrole KSP inhibitor ( 11) that circumvents hERG channel binding and poor in vivo potency, issues that limited earlier compounds from our program. However, introduction of the C2-hydroxymethyl group caused 11 to be a substrate for cellular efflux by P-glycoprotein (Pgp). Utilizing knowledge garnered from previous KSP inhibitors, we found that beta-fluorination modulated the p K a of the piperidine nitrogen and reduced Pgp efflux, but the resulting compound ( 14) generated a toxic metabolite in vivo. Incorporation of fluorine in a strategic, metabolically benign position by synthesis of an N-methyl-3-fluoro-4-(aminomethyl)piperidine urea led to compound 30 that has an optimal in vitro and metabolic profile. Compound 30 (MK-0731) was recently studied in a phase I clinical trial in patients with taxane-refractory solid tumors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/jm800386y

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 160

Metadata

Authors
Cox, C. D., Coleman, P. J., Breslin, M. J., Whitman, D. B., Garbaccio, R. M., Fraley, M. E., Buser, C. A., Walsh, E. S., Hamilton, K., Schaber, M. D., Lobell, R. B., Tao, W., Davide, J. P., Diehl, R. E., Abrams, M. T., South, V. J., Huber, H. E., Torrent, M., Prueksaritanont, T., Li, C., Slaughter, D. E., Mahan, E., Fernandez-Metzler, C., Yan, Y., Kuo, L. C., Kohl, N. E., & Hartman, G. D.
Venue
Journal of Medicinal Chemistry
Published
2008-06-25
Volume
51
Issue
14
Pages
4239-4252
ISSN
  • 0022-2623 (ISSN-L)
  • 1520-4804
OpenAlex
W2060962030
Cited by
160
References
1
FWCI
5.28
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Kinesin Spindle Protein (KSP) Inhibitors. 9. Discovery of (2 S)-4-(2,5-Difluorophenyl)-N-[(3 R,4 S)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1 H-pyrrole-1-carboxamide (MK-0731) for the Treatment of Taxane-Refractory Cancer. https://app.cochat.ai/papers/10.1021/jm800386y
The paper
Cox, C. D., Coleman, P. J., Breslin, M. J., Whitman, D. B., Garbaccio, R. M., Fraley, M. E., Buser, C. A., Walsh, E. S., Hamilton, K., Schaber, M. D., Lobell, R. B., Tao, W., Davide, J. P., Diehl, R. E., Abrams, M. T., South, V. J., Huber, H. E., Torrent, M., Prueksaritanont, T., . . . Hartman, G. D. (2008). Kinesin Spindle Protein (KSP) Inhibitors. 9. Discovery of (2 S)-4-(2,5-Difluorophenyl)-N-[(3 R,4 S)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1 H-pyrrole-1-carboxamide (MK-0731) for the Treatment of Taxane-Refractory Cancer. Journal of Medicinal Chemistry. https://doi.org/10.1021/jm800386y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.